Direct-acting antiviral agents for chronic hepatitis C genotype 1
Genotype 1 CHC is the most prevalent form of CHC infection in Canada, and it is also the least responsive to PR treatment. Despite the availability of boceprevir and telaprevir, a substantial unmet need remains. The treatment burden is high for regimens that require 48 weeks of therapy, and for trea...
| Main Author: | |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa, Ontario
Canadian Agency for Drugs and Technologies in Health
October 2014, 2014
|
| Series: | CADTH therapeutic review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliograpical references